DBV Technologies launches its third Viaskin® program, a first for the treatment of House Dust Mites (HDM) allergy in young children

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: DBV Technologies, (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, announced today the launch of its third Viaskin programme in the treatment of House Dust Mites (HDM) allergy. Viaskin® HDM’s development aims to demonstrate - for the first time ever - safe desensitization in young children allergic to house dust mites. This programme will be carried out in the framework of ImmunAVia, a €16.

Feed Date: 
November 14, 2012